Prostate-specific membrane antigen expression in melanoma metastases
Source: MDLinx, July 2020
This study is done to assess the performance of prostate-specific membrane antigen (PSMA) immunohistochemistry on resected melanoma metastases, to ultimately determine its use as a diagnostic imaging biomarker for melanoma.
Experts stained 41 specimens with stage III/IV melanoma with PSMA immunohistochemistry.
All specimens needed both disease and control regions.